No results for ‘’
Dishman Carbogen Amcis Ltd
₹167.25
(0.14%)
Sat, 19 Sept 2026, 01:29 pm
Health Technology
Pharmaceuticals: Major
24.5KDishman Carbogen Amcis PE Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 28.44 | 18.72 | 19.63 | 5.63 | 14.93 | 10.10 | 6.52 | 5.56 | 6.17 | 11.24 | 15.84 | 32.18 | 33.47 | 16.07 | 5.44 | 0 | 161.18 | 0 | 0 | 1050 |
| Price to book ratio | 6.95 | 4.81 | 4.01 | 1.16 | 2.19 | 0.94 | 0.40 | 0.54 | 0.57 | 1.09 | 1.87 | 0.97 | 1.01 | 0.63 | 0.15 | 0.30 | 0.52 | 0.34 | 0.66 | 0.59 |
| Price to sales ratio | 5.24 | 2.98 | 2.92 | 0.78 | 1.89 | 0.83 | 0.33 | 0.44 | 0.49 | 0.86 | 1.74 | 2.85 | 3.11 | 1.75 | 0.43 | 0.89 | 1.40 | 0.83 | 1.45 | 1.30 |
| Price to cash flow ratio | 89.86 | 59.44 | 123.27 | 9.58 | 6.65 | 5 | 4.05 | 7.51 | 2.42 | 6.26 | 12.77 | 17.75 | 26.98 | 14.07 | 1.58 | 3.41 | 9.01 | 12.02 | 12.61 | 15.06 |
| Enterprise value | 1635Cr | 2249Cr | 2967Cr | 1502Cr | 2456Cr | 1649Cr | 1196Cr | 1421Cr | 1519Cr | 2229Cr | 3596Cr | 5542Cr | 6106Cr | 4306Cr | 1953Cr | 2874Cr | 4266Cr | 3794Cr | 5568Cr | 5262Cr |
| Enterprise value to EBITDA ratio | 25.70 | 19.58 | 19.39 | 5.43 | 11.90 | 10.14 | 5.16 | 4.82 | 4.74 | 7.37 | 9.53 | 14.08 | 14.09 | 9.53 | 4.10 | 10.20 | 14.21 | 10.59 | 24.15 | 13.20 |
| Debt to equity ratio | 1.73 | 1.76 | 1.15 | 1.03 | 0.99 | 0.99 | 0.91 | 0.86 | 0.75 | 0.75 | 0.65 | 0.20 | 0.21 | 0.19 | 0.24 | 0.28 | 0.33 | 0.38 | 0.41 | 0.41 |
| Return on equity % | 30.30 | 36.19 | 26.86 | 22.90 | 15.77 | 9.62 | 6.27 | 10.23 | 9.90 | 9.92 | 12.73 | 4.64 | 3.12 | 4.01 | 2.86 | -2.89 | 0.32 | -0.52 | -2.68 | 0.06 |
Dishman Carbogen Amcis Ltd Price to Earnings Ratio
The Dishman Carbogen Amcis Ltd Price to Earnings Ratio is a key financial metric used by investors to evaluate Dishman Carbogen Amcis Ltd's valuation, profitability, and overall financial performance. Tracking the Dishman Carbogen Amcis Ltd Price to Earnings Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Dishman Carbogen Amcis Ltd (NSE: DCAL, BSE: 540701) is currently trading at ₹167.25, with a market capitalization of ₹2622.98Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Dishman Carbogen Amcis Ltd Price to Earnings Ratio is essential for fundamental analysis.
Dishman Carbogen Amcis Ltd Price to Earnings Ratio Current Value
The current Dishman Carbogen Amcis Ltd Price to Earnings Ratio stands at 1050.
The latest Dishman Carbogen Amcis Ltd Price to Earnings Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Dishman Carbogen Amcis Ltd Price to Earnings Ratio Historical Trend
The Dishman Carbogen Amcis Ltd Price to Earnings Ratio has shown the following historical trend:
- 2024: 1050
- 2023: 0
- 2022: 0
- 2021: 161.18
- 2020: 0
The recent rise in Dishman Carbogen Amcis Ltd Price to Earnings Ratio suggests strengthening valuation trends and improving market sentiment.
What Dishman Carbogen Amcis Ltd Price to Earnings Ratio Indicates for Investors
The Dishman Carbogen Amcis Ltd Price to Earnings Ratio plays a crucial role in understanding the company's financial health and valuation.
A higher P/E ratio indicates investors expect strong future earnings growth, while a lower ratio may signal undervaluation.
Dishman Carbogen Amcis Ltd Price to Earnings Ratio Analysis Summary
The Dishman Carbogen Amcis Ltd Price to Earnings Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Dishman Carbogen Amcis Ltd Price to Earnings Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Dishman Carbogen Amcis Ltd Price to Earnings Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.